Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology

Immune-related adverse events on 18F-FDG PET/CT in patients undergoing immune checkpoint inhibitor therapy

Ashwin Singh Parihar and Richard Wahl
Journal of Nuclear Medicine August 2022, 63 (supplement 2) 2720;
Ashwin Singh Parihar
1Mallinckrodt Institute of Radiology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Wahl
1Mallinckrodt Institute of Radiology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

2720

Introduction: Immune checkpoint inhibitors (ICI) act by inducing an anti-tumor immune response, which also leads to collateral immune targeting of the normal tissue, producing undesirable effects. These unique effects are termed as immune related adverse events (irAE) that can involve multiple tissues and organs and have a pooled incidence of ~50-70%. The detection of irAEs is important as it can prompt additional treatment or in severe cases, even cessation of ICI therapy.

18F-FDG PET/CT is frequently utilized for staging and assessing response in patients with various malignancies undergoing ICI therapy. Glucose metabolism targeting functional imaging with 18F-FDG helps in the early detection of several irAEs, even at sub-clinical stages. It is important for readers to be acquainted with the imaging features of irAEs, so that they may be promptly communicated to the referring clinician, and to avoid misdiagnosing them as disease involvement. Studies have also noted the association of appearance of irAEs with favourable treatment outcomes. In this context we present a review of the irAEs that are detected on 18F-FDG PET/CT, emphasizing on the imaging findings, their incidence and clinical relevance and a brief overview of their management.

Methods: We reviewed the medical and imaging records of patients who underwent 18F-FDG PET/CT after initiation of ICI therapy at our institution. Representative cases for irAEs were selected for inclusion in the exhibit, along with the supporting clinical information, treatment details and follow-up.

Results: This exhibit presents the 18F-FDG PET/CT findings in common and uncommon irAEs encountered during ICI therapy. These will be discussed tissue/ organ-system wise, emphasizing on the typical imaging features, clinical relevance, severity and management.

Conclusions: 18F-FDG PET/CT is superior to conventional imaging for detection of immune-related adverse events (irAE), especially those (e.g. pneumonitis, colitis, hypophysitis, adrenal insufficiency) that may require cessation of therapy. Recognition of irAE associated imaging patterns on 18F-FDG PET/CT is important for the interpreting nuclear medicine physicians to avoid mis-diagnosis and facilitate institution of appropriate medical care.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 63, Issue supplement 2
August 1, 2022
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Immune-related adverse events on 18F-FDG PET/CT in patients undergoing immune checkpoint inhibitor therapy
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Immune-related adverse events on 18F-FDG PET/CT in patients undergoing immune checkpoint inhibitor therapy
Ashwin Singh Parihar, Richard Wahl
Journal of Nuclear Medicine Aug 2022, 63 (supplement 2) 2720;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Immune-related adverse events on 18F-FDG PET/CT in patients undergoing immune checkpoint inhibitor therapy
Ashwin Singh Parihar, Richard Wahl
Journal of Nuclear Medicine Aug 2022, 63 (supplement 2) 2720;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Chimeric antigen receptor (CAR) T cells Imaging: Clinical Needs and Strategies for Success
  • Metastatic NUT Midline Carcinoma
  • Radionuclides used in Nuclear Therapeutic Medicine: a brief history, properties and main relevant studies of radionuclides with mass number less than 100
Show more Oncology

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire